Replies to post #941 on Aethlon Medical Inc (AEMD)

[$heff]

AEMD (.47) trying to break the 52-wk high. This will move much higher by next week on anticipated breakthrough news in HCV!
Best, $heff

Aethlon Medical (AEMD.OB) is developing the Hemopurifier filter cartridge as a potentially new and additive treatment for chronic infection with the hepatitis C virus (HCV), in addition to other viral infections (HIV, influenza-pandemic flu), bio-terror agents, and cancer. The Company's filter technology platform combines principles of both dialysis and affinity chromatography to selectively remove unwanted substances from the blood (e.g. viruses) with a coating of a plant protein called a lectin that binds to specific carbohydrate molecules on the surface of some cell membranes which are not normally present in humans.

To conduct human studies in the U.S., AEMD.OB must receive approval from the FDA based on the Company's Investigational Device Exemption (IDE) application, which must be amended for the Company's proposed use in HCV therapy. The Company hopes to schedule a meeting with the FDA during Fall 2009 (11/15/09 is just an estimate for this entry) based on study data generated in India that includes two small clinical trials demonstrating the ability for the Hemopurifier to bind/remove HCV from the blood of infected patients. This data will be presented at the ASN Conference on Oct. 30th.

From BioMedReports.com

AEMD.OB has completed safety and efficacy studies including 12 collaborative in-vitro studies, animal studies, and human studies. In addition, the Company has conducted five years of research + proof of principle studies on the Hemopurifier and is moving towards commercialization on a named-patient basis in India.